About 30 results found for searched term "Multi-kinase-IN-5" (0.251 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M43523 | Multi-kinase-IN-5 | RET |
| Multi-kinase-IN-5 is a promising multi-kinase inhibitory agent. | ||
| M1643 | AEE788 | EGFR/HER2 |
| NVP-AEE 788 | ||
| AEE788 (NVP-AEE788) is a novel multitargeted HER 1/2 and VEGFR 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1. | ||
| M1669 | Regorafenib | VEGFR/PDGFR |
| BAY 73-4506 | ||
| Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively. | ||
| M1805 | OSI-930 | VEGFR/PDGFR |
| OSI-930 is a multi-targeted tyrosine kinase inhibitor of the receptor tyrosine kinases c-Kit and VEGFR-2 with IC50 values of 9.5 and 10.1 nM. | ||
| M1815 | KW-2449 | FLT3 |
| KW2449 | ||
| KW-2449 is a novel multitargeted kinase inhibitor of FLT3, ABL and Aurora kinase with IC50 values of 6.6 nM, 14 nM and 48 nM. | ||
| M1827 | Sorafenib Tosylate | VEGFR/PDGFR |
| BAY 43-9006,Nexavar | ||
| Sorafenib (BAY 43-9006) Tosylate is an orally active multikinase inhibitor of tyrosine protein kinases VEGFR/PDGFR and RAF/MEK/ERK with IC50 values of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. | ||
| M1841 | Lenvatinib | VEGFR/PDGFR |
| E7080 | ||
| Lenvatinib (E7080) is a potent inhibitor of multiple tyrosine kinases, including VEGF-R3 tyrosine kinase (IC50=5.2 nM) and VEGF-R2 tyrosine kinase (IC50=4.0 nM). | ||
| M1956 | Apatinib mesylate | VEGFR/PDGFR |
| Rivoceranib mesylate; YN968D1 | ||
| Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor of VEGFR2 with an IC50 of 2.43 nM. | ||
| M2850 | Midostaurin | PKC |
| PKC412 | ||
| Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM. | ||
| M3026 | Sorafenib (BAY 43-9006) | Raf |
| BAY 43-9006 | ||
| Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. | ||
| M4870 | Cerdulatinib | JAK |
| PRT062070, PRT2070 | ||
| Cerdulatinib (PRT-062070, PRT2070) is an orally active multi-target tyrosine kinase inhibitor with IC50s of JAK1/JAK2/JAK3/TYK2 and Syk 12 nM/6 nM/8 nM/0.5 nM and 32 nM, respectively. It was also able to inhibit the other 19 kinases tested, all with IC50 below 200 nM. | ||
| M5029 | WHI-P180 | CDK |
| Janex 3 | ||
| Whi-p180 (Janex 3) is a multikinase inhibitor; The IC50 values of RET, KDR and EGFR were 5 nM, 66 nM and 4 μM, respectively. | ||
| M6158 | ARQ-087 | FGFR |
| Derazantinib | ||
| ARQ 087 is a novel, ATP competitive, small molecule, multi-kinase inhibitor with potent in vitro and in vivo activity against FGFR addicted cell lines and tumors. ARQ 087 exhibited IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3. | ||
| M7590 | A3 hydrochloride | PKA |
| A-3 hydrochloride | ||
| A-3 Hydrochloride is A potent, cellular permeable, reversible, atP-competitive, non-selective antagonist targeting multiple kinases. A-3 Hydrochloride is an inhibitor of PKA (Ki=4.3 µM), casein kinase II (Ki=5.1 µM), and myosin light chain kinase (MLCK) (Ki=7.4 µM). A-3 hydrochloride also inhibited PKC and casein kinase I activity with Ki of 47 µM and 80 µM, respectively. | ||
| M9009 | Ponatinib hydrochloride | Src-bcr-Abl |
| AP24534 HCl | ||
| Ponatinib hydrochloride is a potent, orally available multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. | ||
| M10227 | Pim1/AKK1-IN-1 | Pim |
| LKB1/AAK1 dual inhibitor | ||
| Pim1/AKK1-IN-1 is a potent multi-kinase inhibitor with Kd values of 35 nM/53 nM/75 nM/380 nM for Pim1/AKK1/MST2/LKB1 respectively. | ||
| M9429 | SU14813 | VEGFR/PDGFR |
| SU-14813 | ||
| SU14813 is a novel multiple receptor tyrosine kinase inhibitor with IC50s of 2, 50, 4, 15 nM for VEGFR-1, VEGFR-2, PDGFR-β and KIT. | ||
| M10327 | Zotiraciclib | CDK |
| TG02; SB1317 | ||
| Zotiraciclib (TG02, SB1317) is an orally bioavailable, brain penetrant multi-kinase inhibitor of CDK2, JAK2, and FLT3 with IC50 values of 13, 73, and 56 nM, respectively. | ||
| M11240 | XL092 | TAM Receptor |
| JUN04542; Zanzalintinib | ||
| XL092 is an orally active, ATP-competitive inhibitor of multireceptor tyrosine kinases (RTKs), including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM and 7.2 nM in cell analysis, respectively. XL092 has antitumor activity. | ||
| M13591 | Cenisertib | Aurora Kinase |
| AS-703569; R-763 | ||
| Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. | ||
| M13592 | ENMD-2076 Tartrate | Aurora Kinase |
| ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively. | ||
| M14898 | Dovitinib lactate | FLT3 |
| CHIR-258 lactate; TKI-258 lactate | ||
| Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. | ||
| M20877 | Toceranib phosphate | VEGFR/PDGFR |
| SU11654 | ||
| Toceranib phosphate is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. | ||
| M27701 | Famitinib | VEGFR/PDGFR |
| SHR1020 | ||
| Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis. | ||
| M27723 | Amuvatinib hydrochloride | c-Kit |
| MP470 hydrochloride; HPK 56 hydrochloride | ||
| Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity. | ||
| M28063 | Famitinib malate | VEGFR/PDGFR |
| SHR1020 malate | ||
| Famitinib (SHR1020) malate, an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib malate induces cell apoptosis. Famitinib malate exerts powerful antitumor activity in human gastric cancer cells and xenografts, it can be used for the research of cancer. | ||
| M28184 | Debio 0617B | STAT |
| Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34+ stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors. | ||
| M29440 | TL12-186 | PROTAC |
| TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include CDK, BTK, FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A (IC50=73 nM) and CDK9/cyclin T1 (IC50=55 nM). | ||
| M30688 | SU14813 maleate | VEGFR/PDGFR |
| SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT. | ||
| M42075 | Ruserontinib | EGFR/HER2 |
| Ruserontinib (SKLB1028) is an orally active multikinase inhibitor of EGFR, FLT3 and Abl, with an IC50 value of 55 nM for human FLT3, and has antitumor activity. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
